Investor Relations

Newsroom

July 8, 2021

Anivive Awarded $500,000 Grant by the FDA for Canine Cancer Studies

July 7, 2021

Anivive Announces Publication Highlighting the First Successful Use of Artificial Intelligence in Diagnosing Valley Fever in Dogs

June 28, 2021

Anivive Expands Specialty Sales Team to Support Rapid National Distribution of LAVERDIA™-CA1 (verdinexor)

June 17, 2021

Anivive Announces Positive Study Results for Antifungal Vaccine to Prevent Canine Valley Fever

June 3, 2021

Anivive Highlighted in Scientific American Article on Breakthrough Fungal Vaccine

May 26, 2021

Anivive Announces Collaboration with MWI Animal Health to Provide Veterinarians with the Newest Lymphoma Treatment for Dogs

January 21, 2021

Anivive Announces FDA Conditional Approval of LAVERDIA™-CA1 (verdinexor) - the First and Only Oral Tablet to Treat Lymphoma in Dogs

View all press releases
Curing Cancer with a Little Blue Pill?!
June 21, 2021

Curing Cancer with a Little Blue Pill?!

Dr. David Bruyette, Anivive's CMO, talks about his company, a pharmaceutical startup looking for medical solutions for unmet needs in the veterinary space, that has created LAVERDIA™-CA1 (verdinexor), the first pill to treat cancer, in this case lymphoma in dogs, which may someday benefit humans, too.

NPR's Dog Talk ® (and Kitties Too!)

Read More
Can a dog vaccine for Valley fever lead to a human one?
June 6, 2021

Can a dog vaccine for Valley fever lead to a human one?

Anivive's work on an antifungal vaccine to prevent canine Valley Fever is referenced in this Freethink article.

Freethink

Read More
Deadly Fungi Are the Newest Emerging Microbe Threat All Over the World
June 1, 2021

Deadly Fungi Are the Newest Emerging Microbe Threat All Over the World

Anivive's work with Dr. John Galgiani and his research team at the Valley Fever Center for Excellence at the University of Arizona College of Medicine is gaining attention as the threat of systemic fungal diseases escalates globally.

Scientific American

Read More
Anivive sprints to market with pet chemotherapy
April 12, 2021

Anivive sprints to market with pet chemotherapy

Anivive Lifesciences Inc. is taking its first pet-specific drug to market after 3.5 years and $5 million in research and development costs.

Orange County Business Journal

Open PDF
FDA endorses canine epilepsy and lymphoma drugs
January 18, 2021

FDA endorses canine epilepsy and lymphoma drugs

Medications from Pegasus Laboratories and Anivive Lifesciences earned conditional approvals.

Today’s Veterinary Business

Read More
Cats point the way to potential COVID-19 remedies
August 31, 2020

Cats point the way to potential COVID-19 remedies

Anivive Lifesciences, is working on a COVID-19 antiviral drug that’s inspired by cats, and it has new preclinical research findings to back up the project.

FierceBiotech

Read More
A drugs life: How David Bruyette’s biotech startup is changing the way veterinary products come to market
June 9, 2019

A drugs life: How David Bruyette’s biotech startup is changing the way veterinary products come to market

Anivive Lifesciences starts with unmet therapeutic needs and employs high-tech research methods to identify compounds that could meet those needs.

DVM 360

Read More

Financial Data

Our financial statement audits have been performed to Public Company Accounting Oversight Board (PCAOB) standards. These standards set the independence and audit requirements for the auditors, the level of financial reporting by the Company and are required for publicly held companies.
Audited Financial Statements